Genetic mutation in RFX6 gene can lead to a new type of diabetes found a new study published in Nature communications journal.
A Scientific research team at the ULB Center for Diabetes Research and the Erasmus Hospital of the ULB has led to the identification of a new type of diabetes caused by a mutation in the gene RFX6.
Neonatal Diabetes may Be Caused by Mutations in the Insulin Gene
Neonatal diabetes which is an unusual form of diabetes may be caused by mutations in the insulin gene that affects very young children and results in lifelong
Advertisement
‘Individuals carrying the RFX6 mutation have a high probability of developing diabetes: it can start early, before the age of 20 years’
Tweet it Now
Scientists from the ULB Center for Diabetes Research and the Erasmus Hospital of the ULB, together with colleagues at the University of Exeter (UK), University of Helsinki (Finland) and Kyoto University (Japan), have identified a new type of diabetes caused by a mutation in the gene RFX6.
Individuals carrying the RFX6 mutation have a high probability of developing diabetes: it can start early, before the age of 20 years, and by the age of 50 years, 80% of the patients might have developed the disease.
![Gene Signature Identified for Diabetes Prediction]( "Gene Signature Identified for Diabetes Prediction")
A gene signature has been identified for diabetes, where 80 small variations in the genes are found to influence the risk for diabetes.
It is transmitted from parents to children and may affect many generations in the same family. RFX6 diabetes often requires insulin treatment because patients have reduced insulin secretion by the pancreas.
Dr. Miriam Cnop, Professor at the ULB Center for Diabetes Research and the Erasmus Hospital, identified in these patients a reduced production of the hormone GIP( Gastric Inhibitory Peptide ) that stimulates insulin secretion.
The hormone GIP is produced by the intestine after eating and is an important regulator of insulin secretion.
RFX6 diabetes is the first type of diabetes discovered to be related to low GIP production.
The identification of this novel disease mechanism suggests that GIP analogs ( drugs with a structure similar to GIP) may provide a novel treatment option for patients with RFX6 diabetes.
These new observations emphasize the need to identify specific forms of diabetes to provide personalized therapy to patients.
Source: Eurekalert
Gene Signature Identified for Diabetes Prediction
A gene signature has been identified for diabetes, where 80 small variations in the genes are found to influence the risk for diabetes.
Advertisement
It is transmitted from parents to children and may affect many generations in the same family. RFX6 diabetes often requires insulin treatment because patients have reduced insulin secretion by the pancreas.
Dr. Miriam Cnop, Professor at the ULB Center for Diabetes Research and the Erasmus Hospital, identified in these patients a reduced production of the hormone GIP( Gastric Inhibitory Peptide ) that stimulates insulin secretion.
The hormone GIP is produced by the intestine after eating and is an important regulator of insulin secretion.
RFX6 diabetes is the first type of diabetes discovered to be related to low GIP production.
The identification of this novel disease mechanism suggests that GIP analogs ( drugs with a structure similar to GIP) may provide a novel treatment option for patients with RFX6 diabetes.
These new observations emphasize the need to identify specific forms of diabetes to provide personalized therapy to patients.
Source: Eurekalert
CRISPR Gene Therapy Via Skin Transplant Treats Diabetes, Obesity
A novel form of gene-therapy done through skin transplantation treats two related and extremely common human ailments such as type-2 diabetes and obesity.
Advertisement
 Monogenic Forms of Diabetes - Frequently Asked QuestionsDo you know which doctor should you consult if you have Monogenic Forms of Diabetes. This and other commonly asked questions about this condition. | Advertisement
|
Advertisement
Recommended Reading
Latest Diabetes News
In type 2 diabetes individuals, regular screening for two key cardiac biomarkers may decrease the risk of cardiovascular disease events.
The US Food and Drug Administration (FDA) clears the 'bionic pancreas' that improves the management of type 1 diabetes, without the need for constant blood sugar testing.
A new study investigated the use of a mathematical model of glucose metabolism to assess continuous glucose monitor data as a metric of dysfunctional glycemic control.
At least 400 medicinal plants effective in decreasing sugar levels in the blood which is critical to control type 2 diabetes identified.
Considering the enormous type 2 diabetes patient population in China, a new oral insulin therapy will improve treatment.